AIM ImmunoTech Inc. converted approximately $1,224,341 of outstanding debt under a Promissory Note dated February 16, 2024 into 5,065,840 shares of common stock at an average conversion price of $0.24 per share. The transaction was executed through five exchange agreements and partitioned promissory notes with Streeterville Capital, LLC between August 31 and September 3, 2026. This equity issuance satisfied the Promissory Note in full, eliminating all amounts owed under that instrument following prior stockholder approval at a special meeting on July 15, 2026. AIM ImmunoTech Inc. operates in the biotechnology industry, focusing on immunotherapy and vaccine development.
